Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.

Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.

Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.

Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.

Abstract: Methods and mixtures for extracting prenylflavonoids from prenylflavonoid-containing hops materials are provided.

Abstract: Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.

Abstract: The present invention provides a process for producing ?-(3-(1,3/1,6)-D-glucan from a cellular source comprising the steps of alkali extraction of the cellular source; water extraction; acid extraction; and water extraction, where at least one step of water extraction includes pasteurization by steam injection to a temperature of about 100° C. for 15 to about 30 minutes. The solid component produced comprises at least ?-70% 1 (1,3/1,6)-D-glucan by dry weight. The present invention also provides a process of producing mannan and manno-protein complexes comprising the steps of collecting a liquid phase obtained in one an alkali extraction step of the ?(3-(1,3/1,6)-D-glucan process; adjusting the pH of the liquid phase to about 5.0-8.0 with an acid; pasteurizing the liquid phase by steam injection to a temperature of about 100° C. for 15 to about 30 minutes; and isolating the mannans and manno-proteins complexes from the pasteurized liquid phase.

Abstract: The present invention provides a method of improving disease management in an animal by administering an effective amount of ?-glucan composition to the animal. The ?-glucan composition comprises at least about 70% ?-(1,3/1,6)-D-glucan by dry weight and a biological activity of at least 20 ?g Bb released per mg of ?-(1,3/1,6)-D-glucan. The method may also result in beneficial secondary effects including an increase in growth efficiency of the animal; an increase in the survival rate of the animal; an increase in the colostrum quality of the animal; and any combination thereof. The ?-glucan composition may also be administered in combination with or prior to a vaccine, leading to an increase in antibody formation; the negative growth responses associated with administration of a vaccine may also be reduced. In the present method, the ?-glucan composition may be administered in combination with an animal feed.

Abstract: Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.